10-K: Neutra Corp. Reports Unaudited Annual Results for Fiscal Year 2024, Cites Ongoing Financial Challenges

Sentiment:

Annual Results 2 August 2024 3:48 PM

Neutra Corp.'s unaudited annual report for fiscal year 2024 reveals a net loss of $233,465 and ongoing concerns about the company's ability to continue as a going concern without additional financing.

Capital raiseThe company states it needs to raise additional funds to implement its business plan.The company intends to pursue capital through public or private financing, as well as borrowing and other sources.There is no assurance that additional funding will be available on favorable terms.

Worse than expectedThe company's revenue decreased significantly year-over-year.The company has a substantial working capital deficit and critically low cash reserves.There is substantial doubt about the company's ability to continue as a going concern.

Summary

Neutra Corp. reported a net loss of $233,465 for the fiscal year ended January 31, 2024, compared to a net loss of $561,417 in the previous year.
The company's revenue decreased to $39,534 from $67,996 in the prior year, primarily from sales of CBD sports creams and Delta-8 THC products.
Cost of goods sold was $25,199, down from $32,690 in the previous year.
General and administrative expenses decreased to $187,123 from $227,974, due to lower consulting and marketing expenses and employee retention tax credits.
The company's working capital deficit was $971,799 as of January 31, 2024.
Neutra's cash on hand was $1,632 as of January 31, 2024, which is insufficient to execute its business plan without additional funding.
The company is dependent on related party advances to fund operating shortfalls and is actively seeking additional financing through public or private offerings, borrowing, and other sources.
Neutra is subject to significant risks associated with federal, state, and local laws and regulations regarding hemp-derived products, including delta-8-THC and other cannabinoids.
The company's future financial prospects are uncertain, and there is no guarantee it will be able to meet its financial obligations.

Sentiment

Score: 2

Explanation: The document paints a very negative picture of the company's financial health and future prospects, with significant concerns about its ability to continue as a going concern. The company's reliance on related party funding and regulatory risks further contribute to the low sentiment.

Positives

The net loss decreased from $561,417 in 2023 to $233,465 in 2024, indicating some improvement in financial performance.
General and administrative expenses decreased, suggesting cost-cutting measures were implemented.
The company received employee retention tax credits which offset labor costs.

Negatives

Revenue decreased significantly from $67,996 to $39,534 year-over-year.
The company has a substantial working capital deficit of $971,799.
Cash on hand is critically low at $1,632.
Neutra is heavily reliant on related party advances to fund operations.
The company is in default on a related party loan.
There is substantial doubt about the company's ability to continue as a going concern.
The company has not paid dividends on shares of common stock and does not expect to in the foreseeable future.

Risks

Neutra faces significant regulatory risks related to the sale of hemp-derived products, including potential crackdowns by the FDA and DEA.
The company's sales are partially dependent on delta-8-THC, which is subject to regulatory uncertainty.
The amended PACT Act makes online sales of certain products difficult or impossible.
The company may be subject to investigations and enforcement actions by various government agencies.
Neutra's ability to continue operations is dependent on securing additional financing, which is not guaranteed.
The company has a history of recurring net losses and negative cash flows from operations.
The company's internal controls over financial reporting are not effective.

Future Outlook

The company anticipates needing additional financing to fund operations and execute its business plan over the next eighteen months, but there is no guarantee that such financing will be available.

Management Comments

Management believes that the material weaknesses set forth above did not have an effect on our financial results.
Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

The company operates in the nutraceutical and cannabis markets, which are subject to evolving regulations and significant competition. The company's reliance on hemp-derived products, particularly delta-8-THC, exposes it to regulatory risks and market volatility.

Comparison to Industry Standards

Neutra's financial performance is significantly below industry standards for companies in the nutraceutical and cannabis sectors, particularly in terms of revenue generation and profitability.
Many companies in the cannabis industry have secured substantial funding and have established more robust supply chains and distribution networks.
Compared to companies like Canopy Growth or Tilray, which have significant revenue and market capitalization, Neutra's financial position is precarious.
The lack of an audit committee and independent directors is also a significant deviation from corporate governance best practices in the industry.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Lack of Audit Committee	The company does not have a functioning audit committee.	Ongoing	This is a material weakness in internal controls and could lead to misstatements in financial reporting.
Lack of Independent Directors	The company does not have a majority of independent members on its board of directors.	Ongoing	This is a material weakness in internal controls and could lead to conflicts of interest and ineffective oversight.

Legal Proceedings

There are no material, active or pending legal proceedings against the company.

Related Party Transactions

The company incurred salary and commission expenses to its CEO, Sydney Jim.
Mr. Jim also paid expenses on behalf of the company and provided cash advances.
The company owes Mr. Jim or entities controlled by him a significant amount in accounts payable and advances payable.
The company is in default on a loan agreement with a related party.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and regulatory uncertainties.
Employees' job security is uncertain due to the company's going concern issues.
Customers may be affected by potential product disruptions due to regulatory actions or financial instability.
Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

The company intends to pursue capital through public or private financing, as well as borrowing and other sources.
Management plans to continue to focus on raising the funds necessary to implement the Companys business plan.
Management will continue to seek out debt financing to obtain the capital required to meet the Companys financial obligations.

Key Dates

Date	Description
January 11, 2011	Neutra Corp. was incorporated in Nevada.
October 2011	Neutra Corp.'s common stock began trading on the OTC Bulletin Board under the symbol NTRR.
November 13, 2015	The board of directors designated 1,000,000 shares of preferred stock as Series E Preferred Stock.
January 23, 2018	Neutra entered into an agreement with Artillery Labs to sell and market natural nutraceuticals online.
August 16, 2019	Neutra Corp. reincorporated in Wyoming.
August 30, 2019	Neutra purchased all of the outstanding stock of Vivis Corporation.
January 2020	The board of directors designated 50,000 shares of preferred stock as Series A Preferred Stock.
July 2020	The board of directors designated 10,000 shares of preferred stock as Series B Preferred Stock.
November 2020	The board of directors designated 40,000 shares of preferred stock as Series C Preferred Stock.
March 11, 2022	The Company entered into a loan agreement for $60,000 with the holder of the Companys Series A and B preferred stock.
December 2, 2022	The Company entered into a convertible note exchange agreement with Lead Enterprises, Inc.
January 31, 2024	End of the fiscal year for which the annual report was filed.
July 31, 2024	Date used for share ownership information.
August 2, 2024	Date of the report and certifications.

Keywords

hemp, cannabis, delta-8-THC, nutraceuticals, CBD, financing, regulatory, financial results, going concern, operating loss

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.